Abstracts Archive - Page 605 of 2607 - ACR Meeting Abstracts

Abstract Number: 1835 • ACR Convergence 2022
Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease
Magdalena Harasimowicz¹, Emily GIlbert², Sarah Yi³ and Rochella Ostrowski⁴, ¹Loyola University Medical Center Department of Internal Medicine, Chicago, IL, ²Loyola University Medical Center Division of Pulmonary and Critical Care Medicine, Maywood, IL, ³Loyola University Stritch School of Medicine, Maywood, IL, ⁴Loyola University Medical Center Division of Rheumatology, Maywood, IL
Background/Purpose: Sarcoidosis is a multiorgan granulomatous disease with a prevalence of 60 per 100,000 in the United States.1 Given the low prevalence of both sarcoidosis…
Abstract Number: 1825 • ACR Convergence 2022
Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study
Shay Brikman¹, Amir Bieber² and Reuven Mader¹, ¹Rheumatic Diseases Unit, Emek Medical Center, Afula, Israel, ²Emek Medical Center, Raanana, Israel
Background/Purpose: Prior studies have shown an association between chondrocalcinosis (CC) and vascular calcifications. In this study, we aimed to assess the presence of vascular calcifications…
Abstract Number: 1833 • ACR Convergence 2022
Intraarticular Morphine in Knee-arthritis – Results of a Randomized Placebo-controlled Trial
Hildrun Haibel¹, Joachim Sieper¹, Denis Poddubnyy², valeria Rios-Rodriguez³, Fabian Proft², Mikhail Protopopov⁴, Judith Rademacher⁴, Sabrina Igel⁵, Peter Martus⁶ and Christoph Stein⁵, ¹Charité - Universitätsmedizin, Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany, ⁶University Hospital Tübingen, Tübingen, Germany
Background/Purpose: The current standard of intraarticular therapy in patients with inflammatory arthritis (e.g. rheumatoid arthritis; RA) or inflammatory exacerbations of osteoarthritis (OA) is the injection…
Abstract Number: 1846 • ACR Convergence 2022
Cardiac Sarcoidosis: An Underdiagnosed, Life-threatening yet Treatable Disease
Patrick Webster¹, Yogita Rochlani² and Konstantinos Loupasakis³, ¹Rheumatology Fellow at Montefiore, New York, NY, ²Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ³Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Cardiac sarcoidosis (CS) is potentially life-threatening and it typically causes heart failure, ventricular arrhythmia, AV block or sudden death. CS has been reported to…
Abstract Number: 1840 • ACR Convergence 2022
The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease Perform Lower Than Expected: Data from a Norwegian Cohort
Jens Vikse¹, Oyvind Midtvedt², Oyvind Molberg³, Bjørg Tilde Svanes Fevang⁴, Oyvind Palm², Torhild Garen², Katrine Brække Norheim⁵, Gunnstein Bakland⁶, Marianne Wallenius⁷ and Anna-Maria Hoffmann-Vold², ¹University of Bergen, Stavanger, Norway, ²Oslo University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Nepal, ⁴Haukeland University Hospital, Bergen, Norway, ⁵Stavanger University Hospital, Stavanger, Norway, ⁶University Hospital of North-Norway, Tromsø, Norway, ⁷St. Olav University Hospital, Trondheim, Norway
Background/Purpose: Milestones in the field of IgG4-related disease (IgG4-RD) include the 2011 Comprehensive Diagnostic Criteria (CDC), the 2019 ACR/EULAR classification criteria, and the recent identification…
Abstract Number: 1842 • ACR Convergence 2022
Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry
Jasmin B. Kuemmerle-Deschner¹, Joerg Henes², Birgit Kortus-Goetze³, Tilmann Kallinich⁴, Prasad T. Oommen⁵, Juergen Rech⁶, Tobias Krickau⁷, Frank Weller-Heinemann⁸, Gerd Horneff⁹, Ales Janda¹⁰, Ivan Foeldvari¹¹, Catharina Schuetz¹², Frank Dressler¹³, Michael Borte¹⁴, Markus Hufnagel¹⁵, Florian Meier¹⁶, Michael Fiene¹⁷, Julia Weber-Arden¹⁸ and Norbert Blank¹⁹, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, ²Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ³Division of Nephrology, University of Marburg, Marburg, Germany, ⁴Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁵Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁶University Clinic Erlangen, Erlangen, Germany, ⁷Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, ⁸Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ⁹Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ¹⁰Department of Pediatrics, University Hospital Ulm, Ulm, Germany, ¹¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ¹²Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, ¹³Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ¹⁴ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, ¹⁵Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹⁶Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ¹⁷Rheumatology Center Greifswald, Greifswald, Germany, ¹⁸Novartis Pharma GmbH, Nuernberg, Germany, ¹⁹Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Treatment of autoinflammatory periodic syndromes with the interleukin-1β inhibitor canakinumab (CAN) has been shown to be safe and effective in clinical trials and in…
Abstract Number: 1838 • ACR Convergence 2022
Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States
Arielle Bensimon¹, Kristina Chen², Ahmed Noman¹, Erica Yim¹, Jason Xenakis³ and Rohit Aggarwal⁴, ¹Analysis Group, Inc., Boston, MA, ²Pfizer Inc., Cambridge, MA, ³Pfizer Inc., New York, NY, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease characterized by muscle weakness, skin rashes, and elevated risk of associated conditions such as interstitial…
Abstract Number: 1849 • ACR Convergence 2022
Characteristics of Patients with Primary Retinal Vasculitis at a Tertiary Referral Center
Akash Gupta¹, Paola Rivera Morales² and Ninani Kombo², ¹Departmnt of Medicine, Yale University School of Medicine, New Haven, CT, ²Department of Ophthalmology & Visual Sciences, Yale School of Medicine, New Haven, CT
Background/Purpose: Primary retinal vasculitis (PRV) refers to inflammation in the retinal vasculature without any infectious etiology, systemic disease association, or concomitant ocular disease. PRV is…
Abstract Number: 1851 • ACR Convergence 2022
Phenotype and Genotype of Adult-onset Adenosine Deaminase 2 Deficiency Patients
Beibei Zu¹, rongrong wang², Xiaorou Wang³, Bingqing Zhang⁴, Na Xu⁴, Chengjin Huang⁴, Min Shen⁵ and Xuejun Zeng⁴, ¹Department of Rheumatology, Xuzhou Central Hospital, XuZhou, China, ²Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China, ³Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Beijing, China, ⁴Department of General Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disease, characterized by early‑onset vasculopathy, fever, strokes, livedoid rash, hepatosplenomegaly, and hematologic dysfunction,…
Abstract Number: 1848 • ACR Convergence 2022
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
Josh Dan¹, Grant Sprow², Josef Concha³, Nilesh Kodali⁴, DeAnna Diaz⁵, Felix Chin⁶, Thomas Vazquez⁷ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Albert Einstein College of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴New Jersey Medical School, Coppell, TX, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷FIU Wertheim College of Medicine, Virginia Beach, VA
Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…
Abstract Number: 1850 • ACR Convergence 2022
Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
Jeffrey Curtis¹, Iain B McInnes², Proton Rahman³, Dafna Gladman⁴, Feifei Yang⁵, Steve Peterson⁵, Alexa Kollmeier⁶, Natalie Shiff⁷, Chenglong Han⁸, May Shawi⁹, William Tillett¹⁰ and Philip J Mease¹¹, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ³Memorial University, St. John's, NL, Canada, ⁴Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁵Department of Immunology, Janssen Global Services, LLC, Horsham, PA, ⁶Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁷Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁸Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁹Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹⁰Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA), a chronic inflammatory disease characterized by peripheral arthritis, axial inflammation, dactylitis, enthesitis, and skin/nail psoriasis, is associated with reduced health-related quality…
Abstract Number: 1347 • ACR Convergence 2022
Poor Health-Related Quality of Life in Patients with Lupus Nephritis
Cristina Arriens¹, Janice Ma², Konrad Pisarczyk², Richard Leff³, Kiruthi Palaniswamy⁴ and Li Long⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Maple Health Group, LLC, New York, NY, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE) associated with considerable morbidity that has a devastating impact…
Abstract Number: 1792 • ACR Convergence 2022
Contemporary Racial/Ethnic Disparities in Emergency Department Visits and Hospitalizations for Gout in the United States – 2019 Nationwide Analysis
Chio Yokose¹, natalie mccormick², na lu³, amit johi⁴, Lesley Jackson⁵, Minna Kohler⁶, Janeth Yinh², yuqing zhang⁷, John Hsu², kenneth saag⁵ and Hyon Choi⁸, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Arthritis Research Canada, Boston, MA, ⁴Regeneron, Boston, MA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Massachusetts General Hospital, Quincy, MA, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout is a highly prevalent inflammatory arthritis with increasing global disease burden in recent years.1,2 A recent analysis3 of the Multiethnic Cohort Study reported…
Abstract Number: 1741 • ACR Convergence 2022
Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model
Leah Huey¹, Kylie Koney¹, Emily Vance¹, Chia-Feng Tsai², Rosalie K. Chu², Marina A. Gritsenko², Ellen Lee¹, Holly Rosenzweig¹ and Ruth Napier¹, ¹Oregon Health & Science University and VA Portland Health Care System, Portland, OR, ²Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA
Background/Purpose: Mutations in the microbial signaling molecule NOD2 cause granulomatous uveitis, arthritis, and dermatitis in Blau Syndrome. We previously showed a novel role for Nod2…
Abstract Number: 1598 • ACR Convergence 2022
Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Philip J Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Jeffrey Neal⁶, Marleen Nys⁷, Tom Lehman⁷, Nikolay Delev⁷, Shimon Korish⁷, Miroslawa Nowak⁷ and Subhashis Banerjee⁷, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis Center of Lexington, University of Kentucky School of Medicine, Lexington, KY, ⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2) that acts by binding to the unique TYK2 regulatory domain,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].